Views & Analysis Orphan drugs: overcoming barriers to market access What manufacturers should consider, after successfully overcoming any HTA hurdles, to achieve market access.
Views & Analysis Transparently opaque: drug list prices versus net prices The pros and cons of keeping drug pricing agreements confidential.
Views & Analysis Demonstrating value – the future for market access With the US joining other countries around the world in demanding definitions and measurements of the value of treatments, the pharma industry faces the challenge of understanding the requireme
Views & Analysis Hung parliament: who will pharma negotiate with on new PPRS? Who could influence the makeup of the new PPRS?
Views & Analysis New UK law to control generic drug prices - implications for... The aims and implications of the Health Service Medical Supplies (Costs) Act 2017.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
